Give your Alpha-1 patients the most administration setting options
WITH FLEXIBILITY TO CHOOSE
The only FDA-approved, self-administration* at home option for patients to help raise their Alpha-1 levels1
*If self-administration is deemed appropriate, ensure that the patient/caregiver receives detailed instructions and adequate training on how to administer in the home or other appropriate setting and has demonstrated the ability to independently administer GLASSIA.
GLASSIA is the first FDA-approved† liquid treatment for Alpha-1 antitrypsin deficiency (AATD).1
GLASSIA’s infusion rate is ~15 minutes.
- GLASSIA’s infusion time is based on a maximum rate of 0.2 mL/kg/min and a recommended dosage of 60 mg/kg1
GLASSIA is an AATD treatment that comes as a ready-to-administer liquid, so your patients and their caregivers will not need to mix anything before their infusion.
- With no reconstitution required, GLASSIA’s ready-to-administer formulation helps decrease administration steps—and the potential for preparation errors1,2
- Each single-use vial of GLASSIA contains approximately 1 gram (1000 mg) of functional Alpha-1 PI in 50 mL of solution1
†GLASSIA was approved by the FDA on July 1, 2010.
Download the GLASSIA Dosage and Administration Guide for dosing and ordering information and step-by-step details on administration for in-office or at-home infusions.
Download the glassiadosage & Administration Guide
If self-administering GLASSIA is right for your patient, we can connect you with resources to help.
GLASSIA is the first and only AATD augmentation therapy approved for self-administration. Training for self-administration is required and there are resources available for patients. They can learn more about self-administration with materials in our Welcome Kit as well as a video that walks them through the steps. Additionally, once you prescribe GLASSIA, we have programs to help your patients get started.
Find ResourcesWhen you and your patient have chosen a treatment path
When your patient is prescribed a Takeda treatment, Takeda Patient Support is dedicated to helping them get the answers, resources, and tools they need.
Stay connected. Stay informed.
Sign up for more information about GLASSIA.
References
- GLASSIA. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023.
- European Medicines Agency. Good practice guide on risk minimisation and prevention of medical errors.
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/good-practice-guide-risk-minimisation-prevention-medication-errors_en.pdf. Accessed September 14, 2023.